In it together? The case for endocannabinoid–noradrenergic interactions in fear extinction by Warren, William G. et al.
Eur J Neurosci. 2021;00:1–19.    | 1wileyonlinelibrary.com/journal/ejn
Received: 16 July 2020 | Revised: 26 January 2021 | Accepted: 17 March 2021
DOI: 10.1111/ejn.15200  
S P E C I A L  I S S U E  R E V I E W
In it together? The case for endocannabinoid– noradrenergic 
interactions in fear extinction
William G. Warren1 |   Eleni P. Papagianni1 |   Carl W. Stevenson1  |   
Christine Stubbendorff1,2
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2021 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
William G. Warren and Eleni P. Papagianni These authors contributed equally to this work. 
Edited by: Giovanni Marsicano  
Abbreviations: 2- AG, 2- arachidonoylglycerol; AEA, anandamide; AR, adrenoreceptor; BA, basal amygdala; BLA, basolateral amygdala; CB1R, 
cannabinoid receptor type 1; CB2R, cannabinoid receptor type 2; CeA, central amygdala; DH, dorsal hippocampus; DβH, dopamine- beta- hydroxylase; eCB, 
endocannabinoid; ERK, extracellular signal- regulated kinase; FAAH, fatty acid amid hydrolase; FPS, fear- potentiated startle; IL, infralimbic cortex; LA, 
lateral amygdala; LC, locus coeruleus; MAGL, monoacyglycerol lipase; mPFC, medial prefrontal cortex; NA, noradrenaline; NET, noradrenaline 
transporter; PL, prelimbic cortex; PTSD, post- traumatic stress disorder; TRPV1, transient receptor potential vanilloid 1; VH, ventral hippocampus.
1School of Biosciences, University of 
Nottingham, Loughborough, UK
2Department of Neuroscience and 
Brain Technologies, Istituto Italiano di 
Tecnologia, Genova, Italy
Correspondence
Christine Stubbendorff, Department of 
Neuroscience and Brain Technologies, 
Instituto Italiano di Tecnologia, Via Morego 
30, 16163 Genova, Italy.
Email: christine.stubbendorff@iit.it
Funding information
Biotechnology and Biological Sciences 
Research Council, Grant/Award Number: 
BB/M008770/1 and BB/P001149/1
Abstract
Anxiety and trauma- related disorders, such as post- traumatic stress disorder (PTSD), are 
debilitating mental illnesses with great personal and socioeconomic costs. Examining 
memory formation and relevant behavioural responding associated with aversive stimuli 
may improve our understanding of the neurobiology underlying fear memory process-
ing and PTSD treatment. The neurocircuitry underpinning learned fear and its inhibition 
through extinction is complex, involving synergistic interactions between different neu-
rotransmitter systems in inter- connected brain areas. Endocannabinoid and noradrenergic 
transmission have both been implicated separately in fear memory processing and PTSD, 
but potential interactions between these systems in relation to fear extinction have re-
ceived little attention to date. Their receptors are expressed together in brain areas crucial 
for fear extinction, which is enhanced by both cannabinoid and noradrenergic receptor ac-
tivation in these areas. Moreover, cannabinoid signalling modulates the activity of locus 
coeruleus noradrenaline (NA) neurons and the release of NA in the medial prefrontal 
cortex, a brain area that is crucial for fear extinction. Interestingly, endocannabinoid– 
noradrenergic system interactions have been shown to regulate the encoding and retrieval 
of fear memory. Thus, noradrenergic regulation of fear extinction may also be driven 
indirectly in part via cannabinoid receptor signalling. In this perspective paper, we collate 
the available relevant literature and propose a synergistic role for the endocannabinoid 
and noradrenergic systems in regulating fear extinction, the study of which may further 
our understanding of the neurobiological substrates of PTSD and its treatment.
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1 |  INTRODUCTION
Anxiety and trauma- related disorders are the most com-
mon psychiatric illnesses, with debilitating consequences 
for the sufferer as well as considerable socioeconomic 
costs (Acheson et  al.,  2012; Hill et  al.,  2018; Papagianni 
& Stevenson,  2019; Stubbendorff & Stevenson,  2020). 
Fear is the emotional state induced by a perceived threat 
that triggers protective defensive behaviours (Bannerman 
et al., 2014). Whereas these responses are generally adap-
tive in healthy individuals, in patients suffering from 
anxiety and post- traumatic stress disorder (PTSD), such re-
sponses can be maladaptive and out of proportion to the sit-
uation. Psychological treatments can have limited efficacy 
and relapse in common, while pharmacological treatments 
can lack efficacy or have unwanted side effects (Singewald 
et al., 2015; Tawa & Murphy, 2013). Uncovering the neu-
rocircuitry governing the processing of fear memories and 
understanding the interactions between the many neuro-
modulators involved may ultimately lead to better treatment 
options for anxiety and PTSD (Likhtik & Johansen, 2019; 
Ney et al., 2021).
The noradrenergic and endocannabinoid (eCB) systems 
are two such neuromodulatory systems that are important 
for learned fear processing. Prominent but separate research 
fields have linked both cannabinoid and noradrenergic sig-
nalling to the retrieval and extinction of learned fear (Atsak 
et al., 2012; Cain et al., 2004; de Oliveira Alvares et al., 2008; 
Do Monte et al., 2010; Giustino & Maren,  2018; Morena 
et al., 2018; Pamplona et al., 2006), and both systems have 
shown promise as potential targets for the treatment of anx-
iety and PTSD (Delahanty et  al.,  2005; Hill et  al.,  2018; 
Krauseneck et  al.,  2010; Papagianni & Stevenson,  2019; 
Singewald et  al.,  2015; Tawa & Murphy,  2013). The eCB 
system is well known for modulating the function of other 
neurotransmitters, including the noradrenaline (NA) sys-
tem. Activation of pre- synaptic cannabinoid receptors sup-
presses neurotransmitter release, with direct implications 
for learned fear processing and anxiety (Atsak et al., 2012; 
Mendiguren et  al.,  2018; Nasehi et  al., ,2016, 2018; Rea 
et al., 2013; Rey et al., 2012; Schlicker & Kathmann, 2001; 
Spiacci et  al.,  2016). Cannabinoid receptors are located at 
the cell bodies and pre- synaptic terminals of noradrenergic 
neurons, and eCB modulation of NA transmission by regu-
lating the activity of NA neurons and release of NA into the 
synapse is well documented (Gobbi et al., 2005; Mendiguren 
& Pineda, 2006; Muntoni et al., 2006; Oropeza et al., 2005; 
Patel & Hillard, 2003). However, although evidence of a role 
for functional interactions between the eCB system and NA 
transmission in innate fear and stress reactivity is well estab-
lished (Carvalho & Van Bockstaele, 2012; Lutz et al., 2015; 
McLaughlin et  al.,  2009; Morena et  al.,  2016; Wyrofsky 
et al., 2019), the involvement of eCB- NA system interactions 
in fear memory processing and PTSD has, so far, received 
much less attention.
This perspective paper focuses on the potential for 
eCB- NA system interactions in regulating fear extinction 
and their implications for PTSD. We begin by providing an 
overview of the different aspects of fear memory processing 
and the key brain areas that comprise its underlying neurocir-
cuitry. We then review the studies implicating first eCB and 
then NA transmission separately in the extinction of learned 
fear and the aetiology of PTSD before outlining functional 
interactions between these two systems. We argue that eCB 
modulation of locus coeruleus (LC) activity and NA trans-
mission is relevant to the regulation of fear extinction. We 
conclude by outlining the future directions for taking this 
area of research forward.
2 |  OVERVIEW OF LEARNED 
FEAR PROCESSING AND THE 
UNDERLYING NEUROCIRCUITRY
Pavlovian fear conditioning is a behavioural model widely 
used to examine the neurobiological processes involved in 
fear learning. In this model, a context or discrete cue is paired 
with an aversive stimulus, resulting in the encoding of an as-
sociative fear memory. Later exposure to the context or cue 
alone results in conditioned fear responses. Memory retrieval 
induced by longer or repeated exposure to the cue or context 
without the aversive stimulus causes extinction of the original 
fear memory. Crucially, extinction learning does not delete 
the original fear memory but is a form of inhibitory learning 
that suppresses the conditioned fear response by producing a 
competing safe memory that reduces fear expression elicited 
by the context or cue (Myskiw et al., 2014; Stubbendorff & 
Stevenson,  2020). However, extinction memories are frag-
ile, and fear relapse is common. In the context of anxiety 
and PTSD, intervention during the acquisition and later con-
solidation of fear memory is rarely feasible, whereas further 
understanding and pharmacological targeting of the neuro-
biological processes involved in fear extinction, which is im-
paired in PTSD, may have clinical applications (Giustino & 
Maren, 2015; Kaplan & Moore, 2011; Singewald et al., 2015).
Extensive research on the brain areas involved has identi-
fied several inter- connected brain regions, including the hip-
pocampus, amygdala, and medial prefrontal cortex (mPFC), 
as crucial for learned fear processing (for reviews see 
Baldi & Bucherelli, 2015; Giustino & Maren, 2015; Marek 
et  al.,  2019; Tovote et  al.,  2015). Synaptic plasticity in the 
basolateral amygdala (BLA), which includes the lateral (LA) 
and basal (BA) amygdala nuclei, is crucial for the acquisition 
of learned fear. Encoding of the CS- US association during 
cued fear conditioning was initially shown to be mediated by 
LA plasticity, whereas BA plasticity is thought to encode the 
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association between the context and US during contextual 
fear conditioning. Recent studies indicate that plasticity in 
the central amygdala (CeA) is also important for acquiring 
learned fear (Maren et al., 2013; Tovote et al., 2015). BLA is 
also involved in fear memory retrieval through its direct and 
indirect projections via the intercalated cells to CeA, which, 
in turn, projects to the hypothalamus and periaqueductal grey 
to mediate the physiological and behavioural responses asso-
ciated with fear expression. More recent evidence indicates 
that the prelimbic (PL) subregion of mPFC and the ventral 
hippocampus (VH) modulate the plasticity underpinning fear 
conditioning and promote fear expression through their re-
ciprocal projections with BLA (Tovote et al., 2015). The dor-
sal hippocampus (DH) processes and relays context- related 
representations to BLA and mPFC via projections through 
VH that are key to the contextual regulation of learned fear 
(Maren et al., 2013).
This integrated fear circuit is also pivotal for contextual 
and cued fear extinction (Baldi & Bucherelli,  2015; Marek 
et  al.,  2019; Tovote et  al.,  2015). Fear extinction requires 
neuronal activity and synaptic plasticity in BLA (Tovote 
et al., 2015). Different mPFC subregions have opposing roles 
in learned fear and its extinction, with PL and the infralimbic 
(IL) area mediating fear expression and extinction, respectively 
(Laurent & Westbrook,  2009; Sierra- Mercado et  al.,  2011). 
Moreover, distinct subsets of BLA neurons with differing pro-
jections to these mPFC subregions mediate fear expression and 
extinction. While BLA output to PL mediates fear expression, 
the projection from BLA to IL mediates fear extinction (Herry 
et al., 2008; Sotres- Bayon et al., 2012; Senn et al., 2014). Top- 
down regulation of amygdala function by mPFC is also im-
portant for learned fear and its extinction. PL projections to 
BLA promote fear expression (Karalis et al., 2016; Knapska 
et  al.,  2012; Park & Chung,  2020), whereas fear extinc-
tion involves IL projections to BLA (Knapska et  al.,  2012; 
Bloodgood et al., 2018) and the intercalated cells, which in-
hibit CeA activity to suppress fear (Quirk et al., 2003; Tovote 
et  al.,  2015). Fear extinction is well known for its context- 
dependency, which involves VH function (Sierra- Mercado 
et  al.,  2011) and its modulation of the prefrontal– amygdala 
circuitry. VH gating of PL- BLA circuit function plays a role in 
fear expression (Jin & Maren, 2015; Kim & Cho, 2017; Orsini 
et al., 2011; Sotres- Bayon et al., 2012), whereas VH regula-
tion of the IL- BLA circuit is crucial for fear extinction (Marek 
et al., 2018; Orsini et al., 2013).
3 |  THE ENDOCANNABINOID 
SYSTEM AND ITS ROLE IN 
REGULATING FEAR EXTINCTION
In recent years, the eCB system has received increased at-
tention as a potential target for treating a range of nervous 
system disorders, including anxiety and PTSD (Carvalho 
& Van Bockstaele,  2012; Lutz et  al.,  2015; Papagianni & 
Stevenson, 2019). The eCB system forms a complex signal-
ling network of endogenous ligands and their receptors that 
modulate synaptic transmission (Castillo et al., 2012; Kano 
et  al.,  2009; Ohno- Shosaku & Kano,  2014). Anandamide 
(AEA) and 2- arachidonoylglycerol (2- AG) are the primary 
endogenous ligands of the eCB system. Both are synthesised 
de novo and “on demand,” typically following Ca2+ influx 
at the post- synaptic terminal (Cadas et al., 1997) (Figure 1). 
AEA is released via the membrane precursor N- arachidono
ylphosphatidylethanolamine when phospholipase D is acti-
vated by GABAergic or glutamatergic receptor stimulation 
(Bennet et al., 2017). 2- AG is synthesised via diacylglycerol 
by diacylglycerol lipase (DAGL) (Ligresti et al., 2016). AEA 
and 2- AG bind to cannabinoid receptors and other targets 
with different affinities. 2- AG has higher affinity than AEA 
for the cannabinoid receptor type 1 (CB1R) and 2 (CB2R), 
which are both G protein– coupled receptors, whereas AEA 
also has high affinity for the transient receptor potential va-
nilloid 1 (TRPV1) channel (Ligresti et al., 2016). CB1Rs are 
expressed on both GABAergic and glutamatergic terminals 
and abundantly expressed throughout the brain, including 
in the BLA, hippocampus and mPFC (Ligresti et al., 2016; 
F I G U R E  1  Schematic representation of endocannabinoid 
(eCB) transmission at GABAergic and glutamatergic (Glu) synapses. 
Anandamide (AEA) is synthesised from N- arachidonoylphosp
hatidylethanolamine (NAPE) by phospholipase D (PLD), while 
2- arachidonoylglycerol (2- AG) is synthesised from diacylglycerol 
(DAG) by diacylglycerol lipase (DAGL). Modulation of fear extinction 
by eCB transmission occurs via cannabinoid receptor type 1 (CB1R) 
signalling. The endocannabinoid transporter (ECT) mediates eCB 
synaptic re- uptake. AEA is preferentially metabolised by fatty acid 
amide hydrolase (FAAH) into arachidonic acid (AA) and ethanolamine 
(Eth), while 2- AG is preferentially metabolised by monoacyglycerol 
lipase (MAGL) into arachidonic acid (AA) and glycerol (Gly).
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McPartland et  al.,  2007), making them ideally positioned 
to influence fear memory processing. The CB2R is mainly 
found peripherally and, to date, the involvement of CB2Rs 
in modulating central neurotransmission remains poorly 
understood (Mendiguren et  al.,  2018). The eCBs medi-
ate retrograde signalling via pre- synaptic CB1Rs to inhibit 
neurotransmitter release, and non- retrograde signalling oc-
curs via eCB activation of post- synaptic CB1Rs and TRPV1 
channels. AEA and 2- AG signalling are tightly regulated 
by transporter- mediated synaptic re- uptake and degradative 
enzymes mediating their metabolism. Fatty acid amide hy-
drolase (FAAH) preferentially metabolises AEA into ara-
chidonic acid and ethanolamine, whereas monoacyglycerol 
lipase (MAGL) metabolises 2- AG into arachidonic acid 
and glycerol (Cravatt et  al.,  1996; Dinh et  al.,  2002). The 
localisation of these enzymes supports the putative nature of 
eCB signalling, with post- synaptic FAAH inhibiting AEA- 
mediated TRPV1 activation and pre- synaptic MAGL inhib-
iting retrograde 2- AG signalling. Subsidiary enzymes (e.g. 
cyclooxygenase- 2) also facilitate eCB degradation (Kozak & 
Marnett, 2002).
We now review the studies showing the involvement 
of the eCB system in regulating fear extinction (Table  1). 
CB1R- deficient (CB1- /- ) mice are unable to extinguish cued 
fear memories (Marsicano et al., 2002). Activation of CB1Rs 
stimulates activation of extracellular signal- regulated kinase 
(ERK) and calcineurin, two signalling pathways implicated 
in the extinction of fear (Cestari et al., 2014; Lin et al., 2003; 
Merlo et al., 2014), in DH. Furthermore, CB1- /-  mice have 
reduced levels of phosphorylated ERK in BLA and mPFC as 
well as decreased levels of calcineurin in the BLA, mPFC, 
DH and VH after extinction training, compared with wild- 
type mice (Cannich et al., 2004). These findings suggest that 
the site- specific activation of ERK and calcineurin that plays 
a role in fear extinction is regulated by CB1R activation 
(Cannich et al., 2004). Research using systemic administra-
tion of various cannabinoid- acting drugs has further eluci-
dated the role of CB1R signalling in fear extinction. Giving 
the CB1R agonist WIN 55,212– 2 prior to extinction train-
ing facilitated the extinction of short- and long- term con-
textual fear (Pamplona et  al., ,2006, 2008). WIN55,212– 2 
given before extinction training also enhanced cued fear 
extinction (Bisby et  al.,  2020). Using a model of trauma 
combining contextual fear conditioning and social isola-
tion, Morena et al.,  (2018) found that WIN55,212– 2 given 
after, but not before, repeated extinction training sessions 
resulted in the long- term facilitation of extinction memory. 
Similarly, another study found no effect of WIN 55,212– 2 
given before cued fear extinction when fear- potentiated star-
tle (FPS) was used as a behavioural measure for fear con-
ditioning (Chhatwal et  al.,  2005). These findings suggest 
that the consolidation period after extinction training may 
be a critical time window where CB1 receptor activation 
can strengthen the stability of long- term fear extinction. 
Intra- cerebroventricular infusion of AM404, an inhibitor of 
eCB re- uptake/metabolism, or systemic administration of 
the FAAH inhibitors AM3506 or URB597 facilitated cued 
and contextual fear extinction resulting from repeated ex-
tinction sessions, which depended on CB1R but not TRPV1 
channel signalling (Bitencourt et  al.,  2008; Gunduz- Cinar 
et al., 2013; Segev et al., 2018). In contrast, another study 
found that URB597 given after, but not before, repeated 
extinction training sessions enhanced long- term extinction 
memory in a model of trauma (Morena et  al.,  2018). The 
MAGL inhibitor JZL184 inhibited cued fear extinction 
in one study (Hartley et  al.,  2016), while another study 
found no effect of this drug on contextual fear extinction 
(Morena et al., 2018). Several studies have shown that the 
CB1R antagonist/inverse agonist rimonabant impairs cued 
and contextual fear extinction (Chhatwal et al., 2005, 2009; 
Marsicano et  al.,  2002; Pamplona et  al.,  2006; Suzuki 
et al., 2004). Taken together, these studies strongly suggest 
that fear extinction is enhanced by CB1R signalling.
In terms of the brain areas involved, contextual fear extinc-
tion increased perisomatic CB1R expression around a subset 
of BLA neurons (Trouche et al., 2013). Infusion of AM3506 
into the BLA facilitated cued fear extinction (Gunduz- Cinar 
et  al.,  2013). Furthermore, infusion of rimonabant into the 
BLA inhibited the short- term extinction of contextual fear 
(Roche et al., 2007), while BLA infusion of JZL184 impaired 
extinction of cued fear (Hartley et  al.,  2016). In contrast, 
Kuhnert et al.,  (2013) found that infusion of the CB1R an-
tagonist/inverse agonist AM251 into the BLA had no effect 
on the extinction of FPS. URB597 infusion into the BLA or 
DH facilitated inhibitory avoidance extinction resulting from 
repeated extinction sessions in a CB1R- dependent manner 
(Segev et al., 2018). DH infusion of WIN55,212– 2 or AM404 
enhanced the extinction of inhibitory avoidance, while infus-
ing AM251 into this area impaired inhibitory avoidance ex-
tinction (Abush & Akirav, 2010). AM251 infusion into the 
DH also impeded the consolidation of contextual fear extinc-
tion (de Oliveira Alvares et al., 2008). PL or IL infusion of 
AM251 impaired the extinction of FPS, while infusing WIN 
55,212– 2 into the IL facilitated extinction in this paradigm 
(Kuhnert et al., 2013; Lin et al., 2009). Taken together, these 
studies provide evidence that CB1R activation in each of the 
different areas of the learned fear circuitry is sufficient to fa-
cilitate fear extinction.
Studies in humans have also linked the eCB system to 
fear extinction, anxiety and PTSD. Different gene variants 
related to eCB transmission are associated with anxiety 
disorders (Demers et al., 2016; Dincheva et al., 2015; Gee 
et al., 2016; Lazary et al.,. ,2009, 2016; Lester et al., 2017). 
Circulating eCB levels were shown to be altered in 
PTSD (Hauer et  al.,  2013; Hill et  al.,  2013; Neumeister 
et al., 2013). In healthy volunteers, the synthetic cannabinoid 
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Effect on fear 
extinction References
CB1- /- KO (CB1R 
deficiency)




WIN 55,212– 2 (CB1R 
agonist)
Systemic injection Cued fear Before extinction ↑ Retention Bisby et al., (2020)
WIN 55,212– 2 Systemic injection Contextual fear Before extinction ↑ Acquisition and 
retention
Pamplona et al., (2008)
WIN 55,212– 2 Systemic injection Contextual fear Before repeated 
extinction
No effect on 
extinction
Morena et al., (2018)
WIN 55,212– 2 Systemic injection Cued fear— FPS Before extinction No effect on 
extinction
Chhatwal et al., (2005)




WIN 55,212– 2 Systemic injection Contextual fear After repeated 
extinction
↑ Retention Morena et al., (2018)
WIN 55,212– 2 mPFC infusion Cued fear— FPS Before extinction ↑ Retention Lin et al., (2009)
WIN 55,212– 2 mPFC infusion Cued fear— FPS Before extinction ↑ Acquisition Kuhnert et al., (2013)
WIN 55,212– 2 DH infusion Inhibitory 
avoidance
Before extinction ↑ Acquisition and 
retention
Abush & Akirav, (2010)
AM404 (eCB reuptake 
inhibitor)
Systemic injection Contextual fear Before repeated 
extinction
↓ Acquisition and 
retention
Bitencourt et al., (2008)
AM404 DH infusion Inhibitory 
avoidance



















Systemic injection Contextual fear Before repeated 
extinction
No effect on 
extinction
Morena et al., (2018)
URB597 Systemic injection Inhibitory 
avoidance
Before extinction ↑ Acquisition and 
retention
Segev et al., (2018)
URB597 Systemic injection Contextual fear After repeated 
extinction
↑ Retention Morena et al., (2018)
URB597 DH infusion Inhibitory 
avoidance
Before extinction ↑ Retention Segev et al., (2018)
URB597 BLA infusion Inhibitory 
avoidance
Before extinction ↑ Retention Segev et al., (2018)
JZL184 (MAGL 
inhibitor)
Systemic injection Contextual fear Before repeated 
extinction
No effect on 
extinction
Morena et al., (2018)
JZL184 Systemic injection Cued fear Before repeated 
extinction
↓ Retention Hartley et al., (2016)
JZL184 Systemic injection Contextual fear After repeated 
extinction
No effect on 
extinction
Morena et al., (2018)
JZL184 BLA infusion Cued fear Before repeated 
extinction
↓ Retention Hartley et al., (2016)
(Continues)
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receptor agonist dronabinol given before extinction train-
ing facilitated the retrieval of cued fear extinction (Rabinak 
et  al.,  2013). Moreover, this effect has been associated 
with increased prefrontal and hippocampal activation, and 
prefrontal– amygdala functional connectivity, at extinction 
retrieval (Rabinak et al., 2014, 2018). A recent study found 
increased plasma AEA levels after subchronic treatment with 
the FAAH inhibitor PF- 04457845, which was also associated 
with potentiated retrieval of cued extinction memory (Mayo 
et al., 2020).
As reviewed above, increased eCB availability or CB1R 
activation facilitates fear extinction and extinction retention 
(Table  1). The eCB system is well known for modulating 
the function of other neurotransmitters and eCB regulation 
of fear extinction likely occurs through interactions with 
neurotransmitter systems directly involved in learned fear 
processing and anxiety (Mendiguren et  al.,  2018; Rea 
et al., 2013; Rey et al., 2012; Schlicker & Kathmann, 2001; 
Spiacci et al., 2016). Noradrenergic signalling plays a vital 
role in regulating fear extinction (see below), and modulation 
of NA transmission by the eCB system is well documented 
(Gobbi et  al., 2005; Mendiguren & Pineda, 2006; Muntoni 
et  al.,  2006; Oropeza et  al.,  2005; Patel & Hillard,  2003). 
However, although evidence of a role for functional interac-
tions between the eCB system and NA transmission in stress 
reactivity and innate fear is well established (Carvalho & Van 
Bockstaele, 2012; Lutz et al., 2015; McLaughlin et al., 2009; 
Morena et al., 2016; Wyrofsky et al., 2019), the significance 
of eCB– NA interactions in fear extinction has been little ex-
plored. We first summarize the evidence for NA regulation of 
fear extinction before discussing how eCB modulation of NA 
transmission might be indirectly involved.
4 |  NORADRENERGIC 
TRANSMISSION AND ITS ROLE IN 
REGULATING FEAR EXTINCTION
Dysregulation of NA transmission has been implicated in the 
pathogenesis of various neuropsychiatric disorders, includ-
ing PTSD (Delahanty et al., 2005; Giustino & Maren, 2018), 
making it a potential target for pharmacological intervention. 
The elevated NA signalling that accompanies high arousal 
states plays a crucial role in encoding maladaptive fear mem-
ories that are resistant to extinction in PTSD, while height-
ened adrenergic transmission is also implicated in PTSD 
symptomatology. However, NA facilitates both fear and ex-
tinction memory formation, which is thought to involve dif-
ferent effects of NA on the relevant circuitry that depend on 
arousal state. In high states of arousal, NA may enhance fear 
conditioning by activating the amygdala and, in turn, inhibit-









Systemic injection Contextual fear Before extinction ↓ Retention Suzuki et al., (2004)
Rimonabant Systemic injection Contextual fear Before extinction ↓ Acquisition Roche et al., (2007)
Rimonabant Systemic injection Cued fear Before extinction ↓ Acquisition and 
retention
Marsicano et al., (2002)
Rimonabant Systemic injection Cued fear Before repeated 
extinction
↓ Retention Pamplona et al., (2006)




Rimonabant Systemic injection Cued fear After extinction No effect on 
extinction
Marsicano et al., (2002)
AM251 mPFC infusion Cued fear— FPS Before repeated 
extinction
↓ Acquisition and 
retention
Kuhnert et al., (2013)
AM251 DH infusion Inhibitory 
avoidance
Before extinction ↓ Retention Abush & Akirav, (2010)
AM251 DH infusion Contextual fear After reactivation ↓ Consolidation and 
Retention
de Oliveira Alvares 
et al., (2008)
AM251 BLA infusion Cued fear— FPS Before extinction No effect on 
extinction
Kuhnert et al., (2013)
Abbreviations: BLA, basolateral amygdala; CB1R, cannabinoid receptor type 1; DH, dorsal hippocampus; eCB, endocannabinoid; FAAH, fatty acid amide hydrolase; 
FPS, fear- potentiated startle; MAGL, monoacyglycerol lipase; mPFC, medial prefrontal cortex.
T A B L E  1  (Continued)
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towards mPFC activation and, consequently, amygdala inhi-
bition to enhance fear extinction (Giustino & Maren, 2018). 
Below, we provide an overview of NA transmission before 
reviewing the evidence for NA regulation of fear extinction.
Noradrenergic neurons in the LC innervate the mPFC, 
hippocampus and amygdala, amongst other brain areas 
(Giustino & Maren,  2018; Hussain et  al.,  2020; Ranjbar- 
Slamloo & Fazlali,  2020; Schwarz & Luo,  2015; Schwarz 
et al., 2015). NA acts by binding to adrenoreceptors (ARs), 
which are G protein- coupled receptors that are also abun-
dantly expressed in these areas (Day et  al.,  1997; McCune 
et al., 1993; Rainbow et al., 1984). ARs are subdivided into 
the α1, α2 and β subtypes, which differ in their affinities for 
NA and their intra- cellular signalling mechanisms. Each AR 
subtype is expressed post- synaptically, but α2- and β- ARs 
can also be expressed pre- synaptically (Figure 2). While ac-
tivating α1- and β- ARs has excitatory effects, α2- AR activa-
tion reduces neuronal excitability and pre- synaptic α2- ARs 
serve as autoreceptors to regulate NA release (Giustino & 
Maren, 2018; MacDonald et al., 1997; Marshall et al., 1999; 
Ordway et al., 1987). NA transmission is terminated through 
NA reuptake into pre- synaptic terminals by the NA trans-
porter (NET), where it undergoes enzymatic degradation by 
monoamine oxidase. Synaptic NA can also be metabolised by 
catechol- O- methyltransferase (Hussain et al., 2020; Katzung, 
2015).
Animal studies have implicated noradrenergic signalling 
in the extinction of fear memories (Table 2). Early studies 
found that central NA depletion resulted in extinction re-
sistance in various aversive learning paradigms (Fibiger & 
Mason, 1978; Mason & Fibiger, 1978, 1979a, 1979b, 1979c; 
but see Tsaltas et al., 1984). Systemic pharmacological inter-
ventions have also been used to assess the complex role of 
AR signalling in fear extinction. The α1- AR antagonist pra-
zosin given after repeated extinction sessions impaired con-
textual fear extinction (Bernardi & Lattal, 2010), but another 
study found no effect of prazosin on cued fear extinction 
(Lucas et al., 2019). When given before cued or contextual 
fear extinction training, the α2- AR antagonist yohimbine en-
hanced the retention of extinction memory (Cain et al., 2004; 
Morris & Bouton, 2007), possibly by blocking pre- synaptic 
autoreceptors and increasing NA release. However, Mueller 
et al., (2009) showed that yohimbine injected prior to cued 
extinction training attenuated fear expression without affect-
ing extinction retention. Of note, there was no effect of yo-
himbine found when administered after cued fear extinction 
training (Cain et  al.,  2004; Morris & Bouton,  2007). The 
β- AR antagonist propranolol given before or after extinction 
training impaired the encoding of contextual fear extinction, 
whereas the β- AR agonist isoproterenol given after contex-
tual fear extinction training facilitated its consolidation (Do- 
Monte et al., 2010). Dopamine- beta- hydroxylase (DβH) is a 
key enzyme in NA biosynthesis, and mice genetically mod-
ified to be DβH- deficient (DβH- /-  mice) showed impaired 
contextual fear extinction, which was rescued by the β- AR 
agonist xamoterol (Ouyang & Thomas,  2005). Moreover, 
propranolol impaired contextual fear extinction in DβH+/-  
mice (Ouyang & Thomas, 2005). Other evidence indicates 
that propranolol administered prior to cued fear extinction 
learning impaired extinction encoding (Cain et  al.,  2004; 
Fitzgerald et  al.,  2015). However, Rodriguez- Romaguera 
et al., (2009) reported that propranolol given before cued ex-
tinction learning attenuated fear expression without affecting 
extinction. Taken together, these studies indicate that NA fa-
cilitates fear extinction via activation of β- ARs and possibly 
also α1- ARs.
In relation to the underpinning neural substrates, cued 
fear extinction learning increased NA tone in the mPFC, and 
the LC- mPFC projection was found to be crucial for suc-
cessful extinction encoding (Hugues et  al.,  2007; Uematsu 
et al., 2017). Local infusion of the β- AR antagonist atenolol 
into mPFC before extinction training impaired contextual 
F I G U R E  2  Schematic representation of noradrenaline (NA) projections from the locus coeruleus (LC) to the fear extinction circuitry (left) 
and neurotransmission at the NA synapse (right). Left) NA- LC neurons project to the medial prefrontal cortex (mPFC), dorsal hippocampus (DH) 
and amygdala (basolateral [BLA] and central [CeA] amygdala). Right) NA regulation of fear extinction occurs via signalling at adrenoreceptors 
subdivided into the α1, α2 and β subtypes expressed pre- and/or post- synaptically. NA re- uptake is mediated by the pre- synaptic NA transporter 
(NET) and NA metabolism occurs via enzymatic degradation (not shown).
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Effect on fear 
extinction References
Microdialysis (NA tone) mPFC Cued fear Before and after 
extinction
NA tone ↑ after 
extinction
Hugues et al., (2007)
NA mPFC infusion Contextual fear After extinction ↓ Consolidation Fiorenza et al., (2012)
NA DH infusion Contextual fear After extinction ↑ Consolidation and 
retention
Chai et al., (2014)
NA DH infusion Contextual fear After extinction No effect on 
extinction
Fiorenza et al., (2012)
NA BLA infusion Contextual fear After repeated 
extinction
↑ Retention Berlau & 
McGaugh, (2006)









Before conditioning ↓ Retention Fibiger & 
Mason, (1978)




Before conditioning ↓ Acquisition and 
retention
Mason et al., (1979a)
6- Hydroxydopamine Dorsal NA bundle 
injection
Passive Avoidance Before conditioning ↓ Acquisition and 
retention
Mason et al., (1979c)










Before conditioning ↑ Acquisition Tsaltaas et al., (1984)
Optogenetic inhibition LC- mPFC 
projections
Cued fear During cue 
presentation during 
extinction
↓ Acquisition and 
retention
Uematsu et al., (2017)
Isoproterenol (β- AR 
agonist)
Systemic injection Contextual fear After repeated 
extinction day
↓ Retention Do- Monte et al., (2010)
BRL37344/SR58611A 
(β- AR agonists)
BLA infusion Cued fear (FPS) Before extinction ↑ Retention Skelly et al., (2016)
Methylphenidate (NA 
reuptake inhibitor)
DH infusion Contextual fear Before extinction ↑ Acquisition and 
retention
Furini et al., (2017)
Prazosin (α1- AR 
antagonist)
Systemic injection Cued fear Before repeated 
extinction
No effect on 
extinction
Lucas et al., (2019)
Prazosin Systemic injection Contextual fear After repeated 
extinction
↓ Retention Bernardi & 
Lattal, (2010)
Yohimbine (α2- AR 
antagonist)
Systemic injection Contextual fear Before extinction ↑ Acquisition Cain et al., (2004)
Yohimbine Systemic injection Cued fear Before extinction ↑ Retention Cain et al., (2004)




Yohimbine Systemic injection Cued fear Before extinction ↑Acquisition Mueller et al., (2009)









   | 9WARREN Et Al.
fear extinction (Do- Monte et  al.,  2010). Propranolol in-
fused into the IL before extinction training impaired cued 
fear extinction, while NA increased neuronal excitability 
in this area in vitro in a β- AR- dependent manner (Mueller 
et al., 2008). Similarly, infusion of NA into the DH immedi-
ately or 12 hr after contextual extinction promoted long- term 
extinction retention, which was blocked by propranolol (Chai 
et al., 2014). DH infusion of methylphenidate, a dopamine/
NA re- uptake inhibitor, before weak extinction training po-
tentiated contextual fear extinction, which was blocked by 
the β- AR antagonist timolol (Furini et al., 2017). Infusion of 
atenolol into the DH after contextual fear extinction blocked 
its encoding in DβH+/-  mice (Ouyang & Thomas, 2005). In 
BLA, post- extinction infusion of NA also enhanced contex-
tual extinction encoding, but propranolol infusion had no 
effect (Berlau & McGaugh,  2006). Taken together, these 
results indicate that NA facilitates fear extinction via β- AR 
activation in the learned fear circuitry. However, other stud-
ies examining β- AR regulation of fear extinction have re-
ported conflicting results. Fiorenza et al.,  (2012) examined 
the effects of infusing NA or timolol into these areas after 
the extinction of contextual fear. NA or timolol infusion into 
the mPFC impaired or enhanced extinction, respectively. In 
the DH, there was no effect of infusing NA or timolol on 
extinction. NA infusion into the BLA had no effect, whereas 
timolol infusion enhanced extinction. These discrepant 
findings might involve differences in the timing of β- AR 
modulation in relation to extinction learning between these 
studies. Skelly et al., (2016) found that infusing BRL37344 
or SR58611A, both agonists of the β3 subtype of β- ARs, into 
the BLA impaired the extinction of FPS, although it is worth 
noting that β3- AR activation mediates inhibition in this area 
(Silberman et al., 2010). The neural locus mediating any fa-
cilitatory effect of α1- AR activation on fear extinction re-
mains to be determined.
Human studies have also examined the association be-
tween NA transmission, learned fear and PTSD. Certain 
gene variants related to NA signalling have been linked to 
emotional memory processing, anxiety or PTSD (Gibbs 
et  al.,  2013; Hommers et  al.,  2018; Liberzon et  al.,  2014; 
Marques et  al.,  2017; de Quervain et  al.,  2007; Rasch 
et  al.,  2009). Urinary NA levels in children immediately 
after trauma exposure predicted long- term PTSD severity 
(Delahanty et al., 2005; Mead et al., 2010). Long- term treat-
ment with the β- AR antagonist metoprolol after cardiac sur-
gery decreased PTSD symptoms in females but not in males 
(Krauseneck et al., 2010). Propranolol given to healthy vol-
unteers before fear retrieval impaired subsequent extinction 
learning (Bos et  al.,  2012). In contrast, healthy volunteers 
given reboxetine, a NA re- uptake inhibitor, after cued fear 
extinction showed no facilitation of long- term extinction re-





Effect on fear 
extinction References
Propranolol (β- AR 
antagonist)
Systemic injection Contextual fear Before extinction ↓ Retention Ouyang & 
Thomas, (2005)
Propranolol Systemic injection Cued fear Before extinction ↓ Retention Cain et al., (2004)
Propranolol Systemic injection Cued fear Before extinction ↑ Acquisition Rodriguez- Romaguera 
et al., (2009)
Propranolol Systemic injection Contextual fear After repeated 
extinction
↓ Retention Do- Monte et al., (2010)
Propranolol mPFC infusion Cued fear Before extinction ↓ Retention Mueller et al., (2008)
Propranolol BLA infusion Contextual fear After repeated 
extinction




Timolol (β- AR 
antagonist)
mPFC infusion Contextual fear After extinction ↑ Consolidation Fiorenza et al., (2012)
Timolol DH infusion Contextual fear After extinction No effect on 
extinction
Fiorenza et al., (2012)
Timolol BLA infusion Contextual fear After extinction ↑ Consolidation Fiorenza et al., (2012)
Atenolol (β- AR 
antagonist)
mPFC infusion Contextual fear Before extinction ↓ Retention Do- Monte et al., (2010)
Atenolol DH infusion Contextual fear After extinction ↓ Consolidation Ouyang & 
Thomas, (2005)
Abbreviations: AR, adrenoreceptor; BLA, basolateral amygdala; DH, dorsal hippocampus; FPS, fear- potentiated startle; LC, locus coeruleus; mPFC, medial prefrontal 
cortex; NA, noradrenaline.
T A B L E  2  (Continued)
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5 |  MODULATION OF 
NORADRENALINE TRANSMISSION 
BY THE ENDOCANNABINOID 
SYSTEM
As mentioned above, functional interactions between eCB 
and NA signalling are implicated in stress responsivity 
and innate fear. Here, we review the different mechanisms 
by which the eCB system can modulate NA transmission, 
which has been examined extensively in the mPFC in par-
ticular, before making the case for eCB– NA interactions po-
tentially being involved in regulating fear extinction. CB1R 
mRNA and protein are moderately distributed in the LC, 
and CB1Rs are present on LC neurons expressing tyrosine 
hydroxylase, an enzyme involved in NA biosynthesis and 
thus a marker for LC- NA neurons (Herkenham et al., 1991; 
Matsuda et al., 1993; Scavone et al., 2010) (Figure 3 left). In 
mPFC, CB1Rs are co- localized pre- synaptically with DβH, 
α2- ARs and NET, indicating their expression on prefron-
tal NA afferents (Cathel et al., 2014; Oropeza et al., 2007; 
Reyes et  al.,  2009; Richter et  al.,  2012). Moreover, Reyes 
et al., (2015) demonstrated that somatodendritic processes in 
mPFC neurons expressing DAGL are innervated by afferents 
co- expressing DβH, NET and CB1Rs (Figure 3 right). This 
suggests that 2- AG modulates NA release by acting at pre- 
synaptic CB1Rs on NA afferents in the mPFC. CB1Rs and 
α2- ARs were also shown to be co- localized post- synaptically 
on mPFC neurons (Cathel et al., 2014; Reyes et al., 2017). 
Therefore, the eCB system is ideally positioned to control 
noradrenergic signalling in the mPFC by modulating LC- NA 
neuron activity, prefrontal NA release and mPFC neuronal 
excitability, which is particularly relevant to fear extinction 
given the prominent role of mPFC in this stage of fear mem-
ory processing.
Studies have shown that systemic pharmacological ma-
nipulations of CB1R signalling modulate basal LC activity. 
The CB1R agonists WIN55,212– 2 and CP55940 acti-
vated LC neurons, as indicated by increased Fos expres-
sion ex vivo (Oropeza et al., 2005; Patel & Hillard, 2003). 
WIN55,212– 2, CP55940 and URB597 increased spon-
taneous LC neuron firing in vivo (Gobbi et  al.,  2005; 
Mendiguren & Pineda,  2006; Muntoni et  al.,  2006). 
Pre- treatment with rimonabant blocked these effects on 
LC activity, indicating their CB1R dependence (Gobbi 
et  al.,  2005; Mendiguren & Pineda,  2006; Muntoni 
et al., 2006; Oropeza et al., 2005). Furthermore, Muntoni 
et al.,  (2006) demonstrated that basal LC activity was di-
minished when rimonabant was administered alone, which 
is indicative of tonic eCB control of LC neurons. In con-
trast, Oropeza et al., (2005) reported no reduction in basal 
cFos expression following rimonabant treatment. However, 
such discrepancies may be attributed to the relative sen-
sitivity of in vivo electrophysiology recordings over ex 
vivo immunohistochemical detection, as well as the ani-
mals being anaesthetised or awake during drug adminis-
tration. Intra- cerebroventricular infusion of WIN55,212– 2 
elicited a similar excitation of LC neurons compared with 
systemic administration (Muntoni et al., 2006). In contrast, 
Mendiguren and Pineda (2006) found no effect of intra- 
cerebroventricular WIN55- 212,2 or CP55940 infusion on 
LC activity. Discrepancies in the effect of ventricular infu-
sions between studies may be due to differences in the doses 
of drug used. However, Mendiguren and Pineda (2006) 
also reported that neither local infusion of WIN55,212– 2 
F I G U R E  3  Schematic representation summarising the possible mechanisms by which endocannabinoid (eCB) signalling modulates prefrontal 
noradrenaline (NA) transmission. Left) The cannabinoid receptor type 1 (CB1R) is present at the synapse of locus ceruleus (LC) NA (LC- NA) 
neurons. CB1R activation increases LC- NA neuron activity directly and/or indirectly via the pre- synaptic modulation of glutamatergic (Glu) 
projections to LC- NA neurons. Right) CB1Rs are expressed at the synapse of NA terminals in medial prefrontal cortex (mPFC) neurons. CB1R 
activation increases prefrontal NA release, which may involve eCB modulation of LC- NA projections to mPFC and/or NA signalling mechanisms 
(e.g. noradrenaline transporter (NET), pre- synaptic α2 autoreceptors, post- synaptic α2 receptors) locally in the mPFC. Abbreviations: 2- AG, 
2- arachidonoylglycerol; BLA, basolateral amygdala; CeA, central amygdala; DAG, diacylglycerol; DAGL, diacylglycerol lipase; DH, dorsal 
hippocampus.
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into the LC nor application of WIN55- 212,2 or CP55940 
on to LC slices affected neuronal firing in vivo or in vitro, 
respectively. This suggests that CB1R regulation of LC ac-
tivity occurs indirectly, possibly via the pre- synaptic mod-
ulation of glutamatergic projections to the LC from other 
areas (Mendiguren & Pineda, 2004, 2007).
Pharmacological evidence indicates that CB1R signal-
ling also modulates prefrontal NA release. Systemic admin-
istration of WIN55- 212,2 increased NA levels in the mPFC 
(Oropeza et al., 2005; Page et al., 2007). While this effect of 
WIN55- 212,2 was reversed by rimonabant, NA efflux was 
unaffected by a lower dose of this CB1R antagonist when 
given alone (Oropeza et al., 2005; Page et al., 2008). However, 
other studies have shown that higher doses of rimonabant also 
increase prefrontal NA release (Need et  al.,  2006; Tzavara 
et al., 2003). There are several possible explanations for why 
both CB1R agonism and antagonism increase NA release in 
the mPFC. CB1R antagonist- induced NA efflux at higher 
doses is consistent with the idea that eCB activation of pre- 
synaptic CB1Rs inhibits neurotransmitter release (Schlicker 
& Kathmann,  2001). This is supported by the finding that 
WIN55- 212,2 applied to mPFC slices inhibited electrically 
evoked NA release in a CB1R- dependent manner (Richter 
et al., 2012). Increased NA efflux induced by CB1R activa-
tion may involve various potential mechanisms. Excitation of 
LC activity by systemic CB1R agonist treatment might be ex-
pected to increase NA release, although Gobbi et al., (2005) 
reported no effect of systemic FAAH inhibition via URB597 
treatment on NA efflux in the mPFC, despite its excitatory 
effect on LC activity. Moreover, WIN55- 212,2 infused into 
the mPFC also increased NA release, indicating a local effect 
of CB1R activation (Page et  al.,  2008). Interestingly, acute 
WIN55- 212,2 treatment desensitized pre- synaptic α2- AR 
autoreceptors in mPFC in vitro and reduced prefrontal NET 
expression ex vivo (Cathel et  al., 2014; Reyes et  al., 2009, 
2012; Richter et al., 2012), both of which could facilitate NA 
efflux. Regardless of the exact mechanism/s involved, the ev-
idence indicates that prefrontal NA release is potentiated by 
CB1R activation. Cathel et al., (2014) also found that post- 
synaptic α2- ARs on mPFC neurons were desensitized by 
WIN55- 212,2. This suggests that CB1R modulation of NA 
transmission might also occur by affecting changes in neuro-
nal excitability mediated by post- synaptic α2- AR signalling 
in the mPFC.
In contrast to mPFC, less research has investigated 
eCB modulation of NA transmission in the DH or BLA. 
WIN55- 212,2 application to DH slices inhibited NA efflux 
elicited by Ca2+, glutamate receptor activation or electrical 
stimulation, which occurred in a CB1R- dependent manner 
(Schlicker et  al.,  1997; Kathman et al., 1999). However, 
another study found that applying the CB1/2R agonist CP 
55,940 or rimonabant to DH slices had no effect on electri-
cally evoked NA release (Gifford et  al.,  1997). Moreover, 
neither WIN55- 212,2 nor rimonabant affected NA efflux in-
duced by electrical stimulation in CB1R+/+ or CB1R- /-  mice 
(Kathmann et al., 2001). Acute AEA or WIN55,212– 2 treat-
ment increased NA levels in the DH ex vivo, and the latter 
effect was CB1R- dependent (Hao et al., 2000; Moranta et al., 
2004, 2006). Another study found that subchronic treatment 
with the eCB transport inhibitor UCM707 had no effect on ex 
vivo NA levels in the DH or amygdala (de Lago et al., 2007). 
URB597 alone had no effect on NA efflux from the BLA in 
vivo, but it did potentiate stress- induced NA release in this 
area (Bedse et al., 2015). Taken together, these studies sug-
gest that eCB signalling might also modulate NA transmis-
sion in the DH and BLA. Potential NA modulation of eCB 
signalling in areas of the learned fear circuitry remains poorly 
understood.
6 |  THE CASE FOR CONSIDERING 
ENDOCANNABINOID– 
NORADRENALINE INTERACTIONS 
IN FEAR EXTINCTION AND POST- 
TRAUMATIC STRESS DISORDER
Converging lines of evidence support the proposition that 
eCB– NA system interactions might contribute significantly 
to regulating fear extinction and, thus, possibly also the treat-
ment of PTSD. As outlined above, both the eCB and NA sys-
tems have been implicated separately in fear extinction and 
PTSD. There is overlap in CB1R and AR expression in the 
brain areas demonstrated to be crucial for learned fear and its 
extinction. Furthermore, there is abundant evidence for eCB 
modulation of NA transmission. Broadly, CB1R activation 
facilitates fear extinction while also increasing LC activity 
and prefrontal NA transmission, which, in turn, is associated 
with augmented fear extinction. Overall, the evidence pre-
sented above suggests that eCB– NA interactions in relation 
to fear extinction are worth exploring.
To our knowledge, no research has yet examined func-
tional interactions between the eCB system and NA trans-
mission in regulating fear extinction. However, recent studies 
have examined the role of eCB– NA system interactions in 
fear conditioning and memory retrieval. Cued and contextual 
fear conditioning were shown to be impaired by systemic ad-
ministration of the CB1R agonist ACPA or BLA infusion of 
the α2- AR agonist clonidine, yohimbine, xamoterol or ateno-
lol (Nasehi et al., 2016, 2018). Whereas a subthreshold dose 
of xamoterol infusion reduced the ACPA- induced impair-
ment of both contextual and cued fear acquisition, atenolol 
infusion enhanced the effect of ACPA but only on cued fear 
acquisition (Nasehi et al., 2018). Moreover, yohimbine infu-
sion enhanced the ACPA- induced impairment of contextual 
but not cued fear acquisition, whereas clonidine infusion af-
fected neither contextual nor cued fear conditioning (Nasehi 
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et al., 2016). This indicates that α2- and β- AR signalling are 
both involved in CB1R modulation of learned fear acquisi-
tion. Another study showed that eCB– NA system interactions 
are also involved in regulating fear memory retrieval. Atsak 
et al.,  (2012) found that WIN55- 212,2 infused into the DH 
impaired contextual fear retrieval, and this effect was blocked 
by co- infusion of propranolol, indicating that β- AR signal-
ling is also involved in CB1R modulation of fear memory 
retrieval. NA infusion into the DH was also found to impair 
contextual fear retrieval, but neither co- infusion of NA and 
AM251 nor AM251 infusion alone had an effect. This sug-
gests that the effect of AR agonism on fear retrieval occurs 
downstream of CB1R activation (Atsak et al., 2012). Taken 
together, these studies provide evidence that learned fear 
processing is regulated by eCB– NA interactions. Given the 
prominent role of mPFC in controlling fear extinction and the 
strong evidence for eCB modulation of NA transmission in 
this area, the role of eCB– NA interactions in learned fear pro-
cessing may well extend to fear extinction. However, more 
research is required to determine if and how functional inter-
actions between the eCB and NA systems in different areas 
of the learned fear circuitry are also involved in regulating 
fear extinction. Below we outline various possible avenues of 
research to address this hypothesis.
Determining the effects of CB1R- acting drugs on LC ac-
tivity or NA release during behavioural testing would allow 
for directly examining the role of eCB modulation of NA 
transmission in regulating fear extinction. Optogenetic or 
chemogenetic manipulation of specific LC- NA projections in 
combination with CB1R ligands given systemically or locally 
during behavioural testing could also be useful in this regard. 
Genetic manipulation of different CB1R signalling mecha-
nisms could be used to determine if altered fear extinction 
is accompanied by perturbations in NA transmission at var-
ious levels (e.g. LC activity, NA release, β- AR signalling). 
Behavioural pharmacology experiments combining sys-
temic administration and/or local infusions of drugs acting 
at CB1Rs and β- ARs could be conducted to directly examine 
the role of eCB– NA system interactions in the different brain 
areas implicated in regulating fear extinction. The involve-
ment of eCB and NA transmission in synaptic plasticity has 
been examined separately (Augustin and Lovinger, 2018; 
Giustino & Maren,  2018; Segev et  al.,  2018) but, to our 
knowledge, no research has investigated a role for eCB– NA 
interactions in the plasticity mechanisms that are thought to 
underpin fear conditioning and its extinction. Our current un-
derstanding of CB1R and AR signalling regulation of fear 
extinction, and of eCB modulation of NA transmission, has 
primarily been obtained from animal models using male sub-
jects. However, clinical evidence indicates that women are 
much more likely than men to develop anxiety and PTSD 
(Day & Stevenson,  2020; Li & Graham,  2017; Ramikie & 
Ressler, 2017). To fully elucidate the role of eCB- NA system 
interactions in fear extinction and PTSD, it is crucial that fu-
ture animal studies incorporate sex into their experimental 
design (Morena et  al., 2021; Ney et  al., 2018). In terms of 
the potential clinical relevance of such research, using direct 
agonists of CB1Rs and/or β- ARs in the treatment of anxi-
ety or PTSD may not be feasible given the psychotropic and 
sympathomimetic side effects, respectively, of using such 
drugs. However, using a combined pharmacological strategy 
of FAAH inhibition together with NET inhibition, which is 
already used to treat these disorders (Bystritsky et al., 2013; 
Murrough et al., 2015), or possibly α2- AR antagonism (e.g. 
yohimbine) to potentiate synaptic NA levels might enhance 
the efficacy of psychological treatments such as exposure 
therapy to reduce fear relapse in the long- term (Giustino & 
Maren, 2018).
7 |  CONCLUSION
Anxiety and PTSD are debilitating illnesses that come at great 
cost both to the sufferer and to society as a whole. As trauma- 
associated fear memories are already firmly consolidated and 
resistant to being extinguished, unravelling the processes of 
fear retrieval and extinction are particularly relevant. The eCB 
and NA systems have been implicated separately in fear ex-
tinction and also as potential targets for PTSD treatment, but 
eCB– NA interactions in relation to fear extinction and PTSD 
have received little attention so far. In this perspective, we have 
demonstrated how CB1R activation facilitates fear extinction 
and increases LC activity and NA transmission in mPFC, the 
latter of which is also associated with augmented fear extinc-
tion. Taken together, these findings suggest that the observed 
effects of NA in regulating fear extinction may be driven in-
directly in part by CB1R signalling. This idea is supported by 
evidence indicating that eCB– NA interactions are involved 
in regulating fear conditioning and retrieval. Our perspective 
paper underlines the importance of studying interactions be-
tween the eCB and NA systems in relation to fear extinction. It 
remains to be determined if eCB– NA interactions are involved 
in regulating the extinction of adaptive and/or maladaptive fear 
memories. Evidence from studies examining eCB regulation 
of extinction in relation to stronger fear memories in animal 
models of trauma indicates that CB1R activation facilitates 
their extinction (Morena et al., 2018; Segev et al., 2018). This 
is encouraging from a translational perspective, but future stud-
ies are needed to investigate the potential role of interactions 
between the eCB and NA systems in mediating fear extinc-
tion in such models. Further work investigating a potential 
role for eCB modulation of NA transmission in biasing fear 
circuit function during different arousal states (Giustino & 
Maren,  2018) might also have clinical benefits in the long- 
term. Therefore, understanding the nature and extent of these 
interactions in regulating fear extinction could have significant 
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implications for understanding the neurobiological substrates 
of anxiety and PTSD.
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